Trusted Resources: Evidence & Education
Scientific literature and patient education texts
New Therapeutic Horizons for Graves’ Hyperthyroidism
source: Endocrine Reviews
year: 2020
authors: Laura C. Lane, Tim D. Cheetham, Petros Perros, Simon H S Pearce
summary/abstract:Graves’ hyperthyroidism is characterized by the presence of autoantibodies that stimulate the thyroid-stimulating hormone receptor (TSHR), resulting in uncontrolled secretion of excessive thyroid hormone. Conventional treatments, including antithyroid medication, radioiodine, or surgery have remained largely unchanged for the past 70 years and either lack efficacy for many patients, or result in lifelong thyroid hormone replacement therapy, in the case of the latter 2 options. The demand for new therapeutic options, combined with greater insight into basic immunobiology, has led to the emergence of novel approaches to treat Graves’ hyperthyroidism. The current therapies under investigation include biologics, small molecules, and peptide immunomodulation.
There is a growing focus on TSHR-specific treatment modalities, which carry the advantage of eliciting a specific, targeted approach, with the aim of avoiding disruption of the functioning immune system. These therapies present a new opportunity to supersede the inadequate treatments currently available for some Graves’ patients, offering hope of successful restoration of euthyroidism without the need for ongoing therapy. Several of these therapeutic options have the potential to translate into clinical practice in the near future. This review provides a comprehensive summary of the recent advances and various stages of development of the novel therapeutic approaches to treat Graves’ hyperthyroidism.
organization: Newcastle University, UK; Newcastle-upon-Tyne Hospitals NHS Foundation Trust, UK; The Great North Children’s Hospital, UKDOI: 10.1210/endrev/bnaa022
read more
Related Content
-
Mark Codner, MD (Deceased)Mark Codner was a Clinical Assistant Pro...
-
Quality of Life Is Worse at 6-10 Years after Radioactive Iodine Treatment of Graves’ Disease as Compared with Anti...Background: Graves’ disease is a comm...
-
Diagnosed With Graves’ Disease Then Thyroid Cancer – LorrieA patient’s thyroid cancer story about...
-
Advances in the Pharmacological Treatment of Graves’ OrbitopathyGraves' orbitopathy has a deteriorating ...
-
The Johns Hopkins Hospital – Thyroid and Parathyroid CenterAt John Hopkins Thyroid and Parathyroid ...
-
Graves’ Disease IntroductionGraves’ disease is a disease affecting...
-
FDA Committee Unanimously Recommends Approval of Teprotumumab for Thyroid Eye DiseaseThe Dermatologic and Ophthalmic Drugs Ad...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.